Managing diabetes with nanomedicine: challenges and opportunities
Nanotechnology-based approaches hold substantial potential for improving the care of patients with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices that enable...
| Main Authors: | , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Nature Publishing Group
2017
|
| Online Access: | http://hdl.handle.net/1721.1/109215 https://orcid.org/0000-0003-4255-0492 https://orcid.org/0000-0001-5629-4798 https://orcid.org/0000-0002-0100-7824 |
| _version_ | 1826202631789346816 |
|---|---|
| author | Langer, Robert S Anderson, Daniel Griffith Veiseh, Omid Tang, Benjamin C. Whitehead, Kathryn Ann |
| author2 | Massachusetts Institute of Technology. Institute for Medical Engineering & Science |
| author_facet | Massachusetts Institute of Technology. Institute for Medical Engineering & Science Langer, Robert S Anderson, Daniel Griffith Veiseh, Omid Tang, Benjamin C. Whitehead, Kathryn Ann |
| author_sort | Langer, Robert S |
| collection | MIT |
| description | Nanotechnology-based approaches hold substantial potential for improving the care of patients with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices that enable more accurate and patient-friendly real-time tracking of blood glucose levels, and are also providing the basis for glucose-responsive nanoparticles that better mimic the body's physiological needs for insulin. Finally, nanotechnology is being used in non-invasive approaches to insulin delivery and to engineer more effective vaccine, cell and gene therapies for type 1 diabetes. Here, we analyse the current state of these approaches and discuss key issues for their translation to clinical practice. |
| first_indexed | 2024-09-23T12:12:04Z |
| format | Article |
| id | mit-1721.1/109215 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T12:12:04Z |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | dspace |
| spelling | mit-1721.1/1092152022-09-28T00:44:22Z Managing diabetes with nanomedicine: challenges and opportunities Langer, Robert S Anderson, Daniel Griffith Veiseh, Omid Tang, Benjamin C. Whitehead, Kathryn Ann Massachusetts Institute of Technology. Institute for Medical Engineering & Science Harvard University--MIT Division of Health Sciences and Technology Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. Department of Chemical Engineering Massachusetts Institute of Technology. Department of Mechanical Engineering Koch Institute for Integrative Cancer Research at MIT Langer, Robert S Anderson, Daniel Griffith Veiseh, Omid Tang, Benjamin C. Whitehead, Kathryn Ann Nanotechnology-based approaches hold substantial potential for improving the care of patients with diabetes. Nanoparticles are being developed as imaging contrast agents to assist in the early diagnosis of type 1 diabetes. Glucose nanosensors are being incorporated in implantable devices that enable more accurate and patient-friendly real-time tracking of blood glucose levels, and are also providing the basis for glucose-responsive nanoparticles that better mimic the body's physiological needs for insulin. Finally, nanotechnology is being used in non-invasive approaches to insulin delivery and to engineer more effective vaccine, cell and gene therapies for type 1 diabetes. Here, we analyse the current state of these approaches and discuss key issues for their translation to clinical practice. Leona M. and Harry B. Helmsley Charitable Trust (Grant 09PG-T1D027) Juvenile Diabetes Research Foundation International (17-2007-1063) Juvenile Diabetes Research Foundation International (3-2013-178) Juvenile Diabetes Research Foundation International (3-2011-310) United States. National Institutes of Health (EB000244) United States. National Institutes of Health (EB000351) United States. National Institutes of Health (DE013023) United States. National Institutes of Health (CA151884) 2017-05-19T17:02:33Z 2017-05-19T17:02:33Z 2014-11 Article http://purl.org/eprint/type/JournalArticle 1474-1776 1474-1784 http://hdl.handle.net/1721.1/109215 Veiseh, Omid, Benjamin C. Tang, Kathryn A. Whitehead, Daniel G. Anderson, and Robert Langer. “Managing Diabetes with Nanomedicine: Challenges and Opportunities.” Nature Reviews Drug Discovery 14, no. 1 (November 28, 2014): 45–57. https://orcid.org/0000-0003-4255-0492 https://orcid.org/0000-0001-5629-4798 https://orcid.org/0000-0002-0100-7824 en_US http://dx.doi.org/10.1038/nrd4477 Nature Reviews Drug Discovery Creative Commons Attribution-Noncommercial-Share Alike http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Nature Publishing Group PMC |
| spellingShingle | Langer, Robert S Anderson, Daniel Griffith Veiseh, Omid Tang, Benjamin C. Whitehead, Kathryn Ann Managing diabetes with nanomedicine: challenges and opportunities |
| title | Managing diabetes with nanomedicine: challenges and opportunities |
| title_full | Managing diabetes with nanomedicine: challenges and opportunities |
| title_fullStr | Managing diabetes with nanomedicine: challenges and opportunities |
| title_full_unstemmed | Managing diabetes with nanomedicine: challenges and opportunities |
| title_short | Managing diabetes with nanomedicine: challenges and opportunities |
| title_sort | managing diabetes with nanomedicine challenges and opportunities |
| url | http://hdl.handle.net/1721.1/109215 https://orcid.org/0000-0003-4255-0492 https://orcid.org/0000-0001-5629-4798 https://orcid.org/0000-0002-0100-7824 |
| work_keys_str_mv | AT langerroberts managingdiabeteswithnanomedicinechallengesandopportunities AT andersondanielgriffith managingdiabeteswithnanomedicinechallengesandopportunities AT veisehomid managingdiabeteswithnanomedicinechallengesandopportunities AT tangbenjaminc managingdiabeteswithnanomedicinechallengesandopportunities AT whiteheadkathrynann managingdiabeteswithnanomedicinechallengesandopportunities |